Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Progress in complete androgen blockade

J Trachtenberg1

  • 1Department of Surgery, University of Toronto, Canada.

European Urology
|January 1, 1997
PubMed
Summary
This summary is machine-generated.

Complete androgen blockade (CAB) shows mixed survival results for advanced prostate cancer. A large National Cancer Institute trial aims to definitively resolve the controversy surrounding its effectiveness compared to castration alone.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Prostate Cancer Rehabilitation Clinic: a biopsychosocial clinic for sexual dysfunction after radical prostatectomy.

Current oncology (Toronto, Ont.)·2019
Same author

Enablers and barriers in delivery of a cancer exercise program: the Canadian experience.

Current oncology (Toronto, Ont.)·2015
Same author

Evaluation of models predicting insignificant prostate cancer to select men for active surveillance of prostate cancer.

Prostate cancer and prostatic diseases·2015
Same author

The impact of a BRCA2 mutation on mortality from screen-detected prostate cancer.

British journal of cancer·2014
Same author

A pilot 'window of opportunity' neoadjuvant study of metformin in localised prostate cancer.

Prostate cancer and prostatic diseases·2014
Same author

Effect of total-body prehabilitation on postoperative outcomes: a systematic review and meta-analysis.

Physiotherapy·2014
Same journal

Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics.

European urology·2026
Same journal

Re: Twelve-month Results from the CISTO Study Comparing Radical Cystectomy Versus Bladder-sparing Therapy for Recurrent High-grade Non-muscle-invasive Bladder Cancer: Recurrent High-risk NMIBC: One Bladder, Choose Wisely.

European urology·2026
Same journal

Re: Dries Develtere, Riccardo Bertolo. Cumulative Genitourinary Toxicity After Prostate Radiotherapy: High-Level Long-Term Randomized Evidence. J Clin Oncol. Online ahead of print. http://dx.doi.org/10.1200/JCO-26-00436.

European urology·2026
Same journal

In Memory of Paul Mitrofanoff (1934-2025).

European urology·2026
Same journal

Re: McKay RR, Pal S, Xie W, et al. Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert Consensus on the Management of Renal Cell and Urinary Tract Cancers. CA Cancer J Clin 2026;76:e70052.

European urology·2026
Same journal

Re: Ultra-hypofractionated Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma: 5-year Outcomes from a Pooled Analysis of the FASTRACK Trials.

European urology·2026
See all related articles

Area of Science:

  • Oncology
  • Urology
  • Clinical Trials

Background:

  • Complete androgen blockade (CAB) has demonstrated survival benefits in some studies for advanced prostate cancer.
  • Contradictory findings exist, with smaller trials and a meta-analysis showing no significant survival advantage for CAB over castration alone.
  • Methodological weaknesses in previous analyses necessitate further investigation.

Purpose of the Study:

  • To definitively determine the survival benefit of complete androgen blockade (CAB) compared to castration alone in patients with symptomatic advanced prostate cancer.
  • To resolve the ongoing controversy regarding the efficacy of CAB.

Main Methods:

  • A large, well-designed trial (National Cancer Institute Intergroup - NCI INT-0105) randomized 1,347 men.
  • Participants received either orchidectomy plus flutamide or orchidectomy plus placebo.

Related Experiment Videos

  • The study design aimed to provide a definitive answer to the CAB controversy.

    • Main Results:

    • Results from the NCI INT-0105 trial are anticipated to provide a definitive answer.
    • Previous meta-analyses showed non-significant improvements with CAB, though sensitivity analyses suggested a benefit.

    Conclusions:

    • The NCI INT-0105 trial is expected to clarify the role of complete androgen blockade in advanced prostate cancer management.
    • Definitive conclusions regarding CAB's survival advantage await the results of this large-scale, randomized trial.